Cargando…

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine

Extranodal NK/T cell lymphoma (ENKL) is a rare entity, associated with an aggressive clinical behavior and poor prognosis. The optimal treatment strategies, particularly for relapsed patients, have not been clearly determined. A 40-year-old female ENKL patient with orbital involvement as the first p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chen, He, Hongmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574062/
https://www.ncbi.nlm.nih.gov/pubmed/28855986
http://dx.doi.org/10.3892/mco.2017.1364
_version_ 1783259765287157760
author Chen, Chen
He, Hongmin
author_facet Chen, Chen
He, Hongmin
author_sort Chen, Chen
collection PubMed
description Extranodal NK/T cell lymphoma (ENKL) is a rare entity, associated with an aggressive clinical behavior and poor prognosis. The optimal treatment strategies, particularly for relapsed patients, have not been clearly determined. A 40-year-old female ENKL patient with orbital involvement as the first presentation was initially suspected to have an orbital pseudotumor. When the patient developed disease progression following treatment with methylprednisolone, biopsy of the orbital mass was performed. Histopathological examination of the biopsy specimen was consistent with the diagnosis of ENKL (Ann Arbor stage IE). The patient was then treated with radiotherapy followed by chemotherapy with dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE regimen). Despite an initial good response, the patient developed disease relapse and progression (stage IIIE). Subsequently, treatment was switched to a novel regimen comprising bortezomib and fludarabine as salvage therapy for two courses. A positron emission tomography scan revealed disappearance of the orbital tumor. The patient then received autologous hematopoietic stem cell transplantation. At the last follow-up (March 2017), the patient remained disease-free.
format Online
Article
Text
id pubmed-5574062
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-55740622017-08-30 Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine Chen, Chen He, Hongmin Mol Clin Oncol Articles Extranodal NK/T cell lymphoma (ENKL) is a rare entity, associated with an aggressive clinical behavior and poor prognosis. The optimal treatment strategies, particularly for relapsed patients, have not been clearly determined. A 40-year-old female ENKL patient with orbital involvement as the first presentation was initially suspected to have an orbital pseudotumor. When the patient developed disease progression following treatment with methylprednisolone, biopsy of the orbital mass was performed. Histopathological examination of the biopsy specimen was consistent with the diagnosis of ENKL (Ann Arbor stage IE). The patient was then treated with radiotherapy followed by chemotherapy with dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE regimen). Despite an initial good response, the patient developed disease relapse and progression (stage IIIE). Subsequently, treatment was switched to a novel regimen comprising bortezomib and fludarabine as salvage therapy for two courses. A positron emission tomography scan revealed disappearance of the orbital tumor. The patient then received autologous hematopoietic stem cell transplantation. At the last follow-up (March 2017), the patient remained disease-free. D.A. Spandidos 2017-10 2017-08-04 /pmc/articles/PMC5574062/ /pubmed/28855986 http://dx.doi.org/10.3892/mco.2017.1364 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Chen, Chen
He, Hongmin
Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
title Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
title_full Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
title_fullStr Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
title_full_unstemmed Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
title_short Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
title_sort treatment of relapsed extranodal natural killer/t-cell lymphoma with bortezomib plus fludarabine
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574062/
https://www.ncbi.nlm.nih.gov/pubmed/28855986
http://dx.doi.org/10.3892/mco.2017.1364
work_keys_str_mv AT chenchen treatmentofrelapsedextranodalnaturalkillertcelllymphomawithbortezomibplusfludarabine
AT hehongmin treatmentofrelapsedextranodalnaturalkillertcelllymphomawithbortezomibplusfludarabine